Anupriya Singhal, Bob T. Li & Eileen M. O’Reilly
Nature Magazine, April 18, 2024
This piece in Nature Medicine that outlines the strategic thinking and future directions in the KRAS battle. Combination therapies against KRAS are underway, and first-in-human clinical trials of new allele specific molecules are already here, including promising inhibitors of KRAS G12D.
Apart from furthering our advances against lung cancers, we have a comprehensive plan to beat some of the most recalcitrant malignancies.
The full article is behind a paywall at Nature Magazine.
JAMA Network, April 12, 2024
Assessing the current global state of adoption of decentralized trial technologies, understanding factors that may be driving or preventing adoption, and highlighting aspirations and direction for industry to enable more patient-centric trials.
Read the report on JAMA Network
Bloomberg New Economy Forum, November 2023
Dr Bob Li, Physician Ambassador to China and Asia-Pacific, Memorial Sloan Kettering Cancer Center and C4C Task Force member, speaks at the 2023 Bloomberg New Economy Forum in Singapore.
Watch the full talk on YouTube
Forbes China, September 2023
Forbes China announced its fourth Forbes China Healthcare Summit will take place virtually on Sept. 22, 2023 in the U.S. (Sept. 23, 2023 in China). The theme of this year’s summit will be “Advancing Global Health Equity To Cure Cancer”.
Read the announcement here.
Forbes.com, September 20, 2023
C4C’s Dr. Bob Li discusses the need for a greater focus on global inequity, defined as a lack of access to clinical trials and breakthrough research. Today, only less than 5% of cancer patients have access to clinical trials offering potentially life-saving new drugs and treatment breakthroughs.
Oncology Live – June 13, 2023
C4C Taskforce Member Dr Bob T. Li discusses the results of a phase 1/2 study of the first-in-class immune-stimulating antibody conjugate BDC-1001 in patients with advanced HER2-expressing solid tumors.
Watch the interview on Oncology Live
Centerpoint, February 21, 2023
On Centerpoint, Dr. Bob Li joins Doug McKelway to discuss new breakthroughs in the area of precision medicine and its effectiveness against lung cancer.
Watch the full Interview on YouTube
Russell Flannery, Forbes.com, 17 December 2022
Health experts from the United States and China recently engaged in discussions regarding a potential collaboration to accelerate the fight against cancer by participating in multi-regional clinical trials. Following a summit between U.S. President Joe Biden and China President Xi Jinping in Indonesia, potential areas of improvement in the strained relationship between the two countries were identified, with a focus on cancer research and treatment. Jingquan Bi, a key figure in China’s health and drug regulatory sector, expressed optimism about overcoming obstacles related to a confidentiality agreement to allow China’s participation in Project Orbis, an initiative aimed at expediting cancer drug approvals through simultaneous regulatory reviews.
Project Orbis, led by the U.S. FDA Oncology Center of Excellence, involves several countries collaborating to review clinical trial data concurrently, thus reducing the time required for cancer patients to access new drugs and treatments. While eight countries are currently part of Project Orbis, China is not included. Dr. Richard Pazdur, the head of
U.S. FDA’s Oncology Center, highlighted the necessity for pharmaceutical companies to make simultaneous submissions to expedite approvals where significant delays exist. The success of Project Orbis has been evident in facilitating communication among regulatory agencies and establishing uniform standards globally.
Efforts to involve China in Project Orbis may involve addressing complexities in confidentiality agreements and exploring new initiatives such as “Project Pragmatica” aimed at simplifying clinical trials. The collaboration in cancer research between the U.S. and China is seen as a pivotal opportunity to revitalize their relationship, particularly in the context of addressing the significant cancer burden in both countries. Prominent figures such as Kevin Rudd emphasized the importance of successful collaboration in cancer research as a means to inject positive momentum into U.S.-China relations, with potential benefits extending beyond healthcare to broader bilateral dynamics.
To read the full article, visit Forbes.com.
Russell Flannery, Forbes, December 5, 2022
Kevin Rudd, CEO of Asia Society, highlighted the significance of collaboration between the U.S. and China in combating cancer as a means to rejuvenate their relationship post the recent summit between President Joe Biden and President Xi Jinping. The meeting at the G20 summit in Bali emphasized the need to revitalize the U.S.-China bilateral ties following a period of strain. Rudd emphasized that stabilizing the relationship was crucial, with both leaders discussing the importance of establishing security measures and strategic guardrails to manage competition while preserving essential national security aspects such as Taiwan.
Rudd pointed out the potential for collaboration in the fight against cancer between institutions like Memorial Sloan Kettering Cancer Center (MSK) and Chinese Thoracic Oncology Group (CTONG), aligning with President Biden’s Cancer Moonshot Initiative. He stressed the importance of this collaboration not only in finding a cure for cancer but also in advancing cancer treatment research and making it accessible to patients worldwide. The aim is not only to combat cancer but to also manage the disease effectively, as it claims many more lives globally than Covid-19.
The event, which drew an online audience of over 20,000 in China, delved into topics such as international clinical trials with liquid biopsies and biomarker technology for lung cancer treatment. Key figures present included Bob Li from MSK, Yi-Long Wu from CTONG, and Richard Pazdur from the FDA. The focus on leveraging joint efforts in the fight against cancer not only reflects a shared goal of finding a cure but also serves as a platform for diplomatic initiatives aimed at fortifying the U.S.-China relationship through mutually beneficial collaborations in critical health sectors.
To read the full article, visit Forbes.com.
Russell Flannery, Forbes, December 5, 2022
At an online symposium, Kevin Rudd, CEO of Asia Society, highlighted the significance of collaboration between the U.S. and China in the fight against cancer as a means to revitalize their relationship. Following the recent summit between President Joe Biden and President Xi Jinping at the G20 gathering in Bali, Rudd emphasized the potential positive impact that successful cooperation in battling cancer could have on the overall U.S.-China relationship. Prior to the summit, the bilateral relationship between the two nations appeared to be deteriorating, but efforts were made by both leaders at the Bali meeting to stabilize ties.
During the symposium organized by Memorial Sloan Kettering Cancer Center and the Chinese Thoracic Oncology Group, Rudd mentioned the need for a security safety net in the U.S.-China relationship as emphasized by Xi Jinping. American leaders are also advocating for strategic guardrails to protect each side’s strategic red lines while engaging in managed strategic competition. Rudd underscored the importance of stabilizing the relationship by addressing critical national security concerns like Taiwan, while allowing for non-lethal strategic competition in other areas.
Rudd highlighted the room for collaboration in cancer research and treatment between MSK, CTONG, regulators, and businesses in alignment with President Biden’s Cancer Moonshot Initiative. The goal is to find a cure for cancer and advance the trialing of advanced cancer treatment drugs to save lives globally. The symposium, which had over 20,000 online viewers in China, also discussed international clinical trials, liquid biopsies, biomarker technology, and lung cancer treatment, shedding light on the importance of global cooperation in combating cancer, a disease claiming millions of lives annually worldwide.
Read the full article on Forbes.com.
